MicroRNA‑126‑3p suppresses HeLa cell proliferation, migration and invasion, and increases apoptosis via the PI3K/PDK1/AKT pathway

Ichikawa,Ryoko; Kawasaki,Rie; Iwata,Aya; Otani,Sayaka; Nishio,Eiji; Nomura,Hiroyuki; Fujii,Takuma

doi:10.3892/or.2020.7512

MicroRNA‑126‑3p suppresses HeLa cell proliferation, migration and invasion, and increases apoptosis via the PI3K/PDK1/AKT pathway

Authors:
- Ryoko Ichikawa
- Rie Kawasaki
- Aya Iwata
- Sayaka Otani
- Eiji Nishio
- Hiroyuki Nomura
- Takuma Fujii
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Fujita Health University, School of Medicine, Toyoake, Aichi 470‑1192, Japan
Published online on: February 21, 2020 https://doi.org/10.3892/or.2020.7512
Pages: 1300-1308
Copyright: © Ichikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously reported that relative to normal cervical mucus, microRNA 126‑3p (miR‑126‑3p) is present in significantly greater amounts in the cervical mucus of patients with overt cervical cancer or precursor lesions. Here, we investigated the effects of enforced miR‑126‑3p expression in the cervical cancer cell line, HeLa, on proliferation, migration, invasion, apoptosis and protein expression. We transfected HeLa cells with miR‑126‑3p miRNA and found that proliferation, migration and invasion by cell counting, wound healing, cell migration and invasion assay were significantly reduced in these cells relative to those transfected with a negative control mimic. The levels of phosphoinositide 3 kinase (PI3K), phosphorylated 3‑phosphoinositide‑dependent protein kinase‑1 (p‑PDK1) and p‑AKT proteins were lower in the miR‑126‑3p‑transfected cells. Phosphorylated 70S6K (p‑p70S6K), phosphorylated glycogen synthase kinase 3β (p‑GSK3β), phosphorylated S6K (p‑S6K), cyclin D1, phosphorylated p21‑activated kinase 1 (p‑PAK1), Rho associated coiled‑coil containing protein kinase 1 (ROCK1), myotonic dystrophy‑related CDC42‑binding kinases α (MRCKα) and phospholipase C γ1 (p‑PLCγ1) were also downregulated. This suggests that downstream effectors of the PI3K/PDK1/AKT pathway are targets for inhibition by miR‑126‑3p. In contrast, apoptotic‑related proteins including the BCL‑2‑associated agonist of cell death (Bad), B‑cell lymphoma‑extra‑large (Bcl‑xL) and BCL‑2‑associated X (Bax), were all upregulated by miR‑126‑3p, resulting in increased caspase 3/7 activity and apoptosis. Thus, enforced expression of miR‑126‑3p inhibited cell migration and invasion and also induced apoptosis by regulating the PI3K/PDK1/AKT pathway in HeLa cells. Hence, high levels of miR‑126‑3p may inhibit cervical carcinogenesis, and targeting the PI3K/PDK1/AKT pathway via miR‑126‑3p could represent a new approach for treating patients with cervical cancer.

View Figures

View References

1	International agency for research on cancer, GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence. http://gco.iarc.fr/Worldwidein 2012.
2	Gupta S, Kumar P and Das BC: HPV: Molecular pathways and targets. Curr Probl Cancer. 42:161–174. 2018. View Article : Google Scholar : PubMed/NCBI
3	Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, et al: Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 5:11168–11179. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bregar AJ and Growdon WB: Emerging strategies for targeting PI3K in gynecologic cancer. Gynecol Oncol. 140:333–344. 2016. View Article : Google Scholar : PubMed/NCBI
5	Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA and MacKay H: Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 130:269–274. 2013. View Article : Google Scholar : PubMed/NCBI
6	Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW and Schwarz JK: AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS One. 9:e929482014. View Article : Google Scholar : PubMed/NCBI
7	Esteller M: Non-coding RNAs in human disease. Nat Rev Genetics. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
8	Granados López AJ and López JA: Multistep model of cervical cancer: Participation of miRNAs and coding genes. Int J Mol Sci. 15:15700–15733. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ma D, Zhang YY, Guo YL, Li ZJ and Geng L: Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer. Chin Med J (Engl). 125:4270–4276. 2012.PubMed/NCBI
10	Cheung TH, Man KN, Yu MY, Yim SF, Siu NS, Lo KW, Doran G, Wong RR, Wang VW, Smith DI, et al: Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle. 11:2876–2884. 2012. View Article : Google Scholar : PubMed/NCBI
11	Liu D, Liu C, Wang X, Ingvarsson S and Chen H: MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. Cancer Epidemiol. 38:85–92. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ding H, Wu YL, Wang YX and Zhu FF: Characterization of the microRNA expression profile of cervical squamous cell carcinoma metastases. Asian Pac J Cancer Prev. 15:1675–1679. 2014. View Article : Google Scholar : PubMed/NCBI
13	Yu Q, Tong S, Yan J, Hong C, Zhai W and Li Y: Preparative separation of quaternary ammonium alkaloids from Corydalis yanhusuo W. T. Wang by pH-zone-refining counter-current chromatography. J Sep Sci. 34:278–285. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yang Y, Song KL, Chang H and Chen L: Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer. Diagn Pathol. 9:2202014. View Article : Google Scholar : PubMed/NCBI
15	Huang TH and Chu TY: Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. Oncogene. 33:3636–3647. 2014. View Article : Google Scholar : PubMed/NCBI
16	Liu R, Zhang YS, Zhang S, Cheng ZM, Yu JL, Zhou S and Song J: MiR-126-3p suppresses the growth, migration and invasion of NSCLC via targeting CCR1. Eur Rev Med Pharmacol Sci. 23:679–689. 2019.PubMed/NCBI
17	Luo W, Yan D, Song Z, Zhu X, Liu X, Li X and Zhao S: miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. Life Sci. 226:98–106. 2019. View Article : Google Scholar : PubMed/NCBI
18	Fujii T, Shimada K, Tatsumi Y, Fujimoto K and Konishi N: Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun. 456:183–189. 2015. View Article : Google Scholar : PubMed/NCBI
19	Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One. 6:e166172011. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
21	Yu Q, Liu SL, Wang H, Shi G, Yang P and Chen XL: miR-126 suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin. Asian Pac J Cancer Prev. 14:6569–6572. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kawai S, Fujii T, Kukimoto I, Yamada H, Yamamoto N, Kuroda M, Otani S, Ichikawa R, Nishio E, Torii Y, et al: Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia. Sci Rep. 8:70702018. View Article : Google Scholar : PubMed/NCBI
23	Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. J Transl Med. 12:2592014. View Article : Google Scholar : PubMed/NCBI
24	Guo C, Sah JF, Beard L, Willson JK, Markowitz SD and Guda K: The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 47:939–946. 2008. View Article : Google Scholar : PubMed/NCBI
25	Xiao J, Lin HY, Zhu YY, Zhu YP and Chen LW: MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway. Onco Targets Ther. 9:5181–5193. 2016. View Article : Google Scholar : PubMed/NCBI
26	Liu LY, Wang W, Zhao LY, Guo B, Yang J, Zhao XG, Hou N, Ni L, Wang AY, Song TS, et al: Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol. 45:1257–1265. 2014. View Article : Google Scholar : PubMed/NCBI
27	Qu Y, Wu J, Deng JX, Zhang YP, Liang WY, Jiang ZL, Yu QH and Li J: MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway. Oncotarget. 7:74217–74226. 2016. View Article : Google Scholar : PubMed/NCBI
28	Meng Q, Wang W, Yu X, Li W, Kong L, Qian A, Li C and Li X: Upregulation of MicroRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem. 116:1613–1623. 2015. View Article : Google Scholar : PubMed/NCBI
29	Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, et al: DIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res. 43((Database Issue)): D153–D159. 2015. View Article : Google Scholar : PubMed/NCBI
30	Temkin SM, Yamada SD and Fleming GF: A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 117:473–476. 2010. View Article : Google Scholar : PubMed/NCBI
31	Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H and Minegishi T: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog. 47:446–457. 2008. View Article : Google Scholar : PubMed/NCBI
32	Tomao F, Di Tucci C, Imperiale L, Boccia SM, Marchetti C, Palaia I, Muzii L and Panici PB: Cervical cancer: Are there potential new targets? An update on preclinical and clinical results. Curr Drug Targets. 15:1107–1120. 2014. View Article : Google Scholar : PubMed/NCBI
33	Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, et al: Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 119:3776–3783. 2013. View Article : Google Scholar : PubMed/NCBI
34	Wilting SM and Steenbergen RDM: Molecular events leading to HPV-induced high grade neoplasia. Papillomavirus Res. 2:85–88. 2016. View Article : Google Scholar : PubMed/NCBI
35	Macville M, Schrock E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, Popescu N and Ried T: Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res. 59:141–150. 1999.PubMed/NCBI
36	Vazquez-Mena O, Medina-Martinez I, Juárez-Torres E, Barrón V, Espinosa A, Villegas-Sepulveda N, Gómez-Laguna L, Nieto-Martinez K, Orozco L, Roman-Basaure E, et al: Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines. PLoS One. 7:e326672012. View Article : Google Scholar : PubMed/NCBI
37	Gonzalez E and McGraw TE: The Akt kinases: Isoform specificity in metabolism and cancer. Cell Cycle. 8:2502–2508. 2009. View Article : Google Scholar : PubMed/NCBI
38	Tavares MR, Pavan IC, Amaral CL, Meneguello L, Luchessi AD and Simabuco FM: The S6K protein family in health and disease. Life Sci. 131:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
39	Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J, Hwang C and Alessi DR: Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 431:245–255. 2010. View Article : Google Scholar : PubMed/NCBI
40	McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L, et al: Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 8:14221–14250. 2017. View Article : Google Scholar : PubMed/NCBI
41	Suprynowicz FA, Kamonjoh CM, Krawczyk E, Agarwal S, Wellstein A, Agboke FA, Choudhury S, Liu X and Schlegel R: Conditional cell reprogramming involves non-canonical β-catenin activation and mTOR-mediated inactivation of Akt. PLoS One. 12:e01808972017. View Article : Google Scholar : PubMed/NCBI
42	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
43	Kim MS, Kim JH, Bak Y, Park YS, Lee DH, Kang JW, Shim JH, Jeong HS, Hong JT and Yoon DY: 2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa human cervical cancer cells. Nutr Cancer. 64:1236–1244. 2012. View Article : Google Scholar : PubMed/NCBI
44	Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA and Avan A: The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy. J Cell Biochem. 118:4163–4169. 2017. View Article : Google Scholar : PubMed/NCBI
45	Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL and Zempolich KA: Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res. 12:250–256. 2006. View Article : Google Scholar : PubMed/NCBI
46	Xie G, Wang Z, Chen Y, Zhang S, Feng L, Meng F and Yu Z: Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response. Cancer Lett. 388:12–20. 2017. View Article : Google Scholar : PubMed/NCBI
47	Cho SY, Choi M, Ban HJ, Lee CH, Park S, Kim H, Kim YS, Lee YS and Lee JY: Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing. Oncotarget. 8:8095–8104. 2017.PubMed/NCBI
48	Gagliardi PA, di Blasio L and Primo L: PDK1: A signaling hub for cell migration and tumor invasion. Biochim Biophys Acta. 1856:178–188. 2015.PubMed/NCBI
49	Xu J, Wang H, Wang H, Chen Q, Zhang L, Song C, Zhou Q and Hong Y: The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1. Hereditas. 156:112019. View Article : Google Scholar : PubMed/NCBI